- 23 August 2019
- 3 min read
Low-cost pill ‘effective at preventing heart disease’
SubscribeResults of a clinical trial into the ‘polypill’ are said to demonstrate for the first time its effectiveness in preventing cardiovascular disease.

Cheap pill helps prevent heart disease
A low-cost pill which contains four different drugs is effective in preventing heart disease and strokes, a study has claimed.
Newly published results of a clinical trial into the “polypill” are said to demonstrate for the first time its effectiveness in preventing cardiovascular disease.
The research claims that, when compared with just receiving lifestyle advice, those who took the polypill reduced their risk of major cardiovascular disease by 34%.
Those without a history of cardiovascular disease saw a risk reduction of around 40% and those with a history of cardiovascular problems saw a reduction of 20%, the study said.
Iranian study published in The Lancet
The results, published in the peer-reviewed medical journal The Lancet, come from a study led by the Tehran University of Medical Sciences in Iran.
The study monitored 6,841 people aged 55 and over who were living in 236 villages in northern Iran.
The villages were randomly divided into two groups, with one made up of 3,417 participants who were given general advice on diet, exercise and smoking.
The second group, containing 3,421 people, was given the same advice, but were also required to take a polypill every day.

After five years, 202 people in the group that took the polypill – which contained aspirin, a statin and two drugs to lower blood pressure – had suffered a heart attack or a stroke, compared with 301 in villages where only lifestyle advice was given.
The study noted that some participants complained of dizziness, muscle pains or indigestion; however, these issues were said to be as common in those not taking the pill.
About this contributor
Nurses.co.uk editorial team
Bringing you a daily update of nursing, NHS, health and social care news from around the UK.
More by this contributorWant to get involved in the discussion?
Log In Subscribe to comment